Disease response outcomes among ixekizumab patients: Findings from the Corrona Registry - 22/08/19
Mona Shahriari, MD, University of Connecticut, Canton, CT; Ryan W. Harrison, MS, Corrona LLC, Waltham, MA; Russel Burge, PhD, Eli Lilly and Company, Indianapolis, IN; Chen-Yen Lin, PhD, Eli Lilly and Company, Indianapolis, IN; William N. Malatestinic, PharmD, MBA, Eli Lilly and Company, Indianapolis, IN; Orin M. Goldblum, MD, Eli Lilly and Company, Indianapolis, IN; David Amato, DO, Eli Lilly and Company, Indianapolis, IN; Margaux Crabtree, MPH, Corrona LLC, Waltham, MA; Elsie Grace, PhD, Eli Lilly and Company, Indianapolis, IN; Mwangi J. Murage, PhD, MPH, Eli Lilly and Company, Indianapolis, IN
Le texte complet de cet article est disponible en PDF.| Supported by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, and Eli Lilly and Company. |
Vol 81 - N° 4S1
P. AB194 - octobre 2019 Retour au numéro
Article précédent
- Discovery of IgG4 anti-gliadin autoantibody as a potential biomarker of psoriasis using an autoantigen array
- Distinguishing between a second primary MCC and a distant cutaneous metastasis—case series and review of literature
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?